Ublituximab FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 10, 2020.
FDA Approved: No
Generic name: ublituximab
Company: TG Therapeutics, Inc.
Treatment for: Chronic Lymphocytic Leukemia
Ublituximab (TG-1101) is an investigational glycoengineered anti-CD20 monoclonal antibody in development for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis (RMS).
Development Timeline for ublituximab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.